These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 35203978)
1. Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION-A 2-Year, Multicenter, Observational, Cohort Study. Butzkueven H; Giacomini PS; Cohan S; Ziemssen T; Sienkiewicz D; Zhang Y; Geissbühler Y; Silva D; Tomic D; Kropshofer H; Trojano M Brain Sci; 2022 Feb; 12(2):. PubMed ID: 35203978 [TBL] [Abstract][Full Text] [Related]
2. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. Cohen M; Maillart E; Tourbah A; De Sèze J; Vukusic S; Brassat D; Anne O; Wiertlewski S; Camu W; Courtois S; Ruet A; Debouverie M; Le Page E; Casez O; Heinzlef O; Stankoff B; Bourre B; Castelnovo G; Rico A; Berger E; Camdessanche JP; Defer G; Clavelou P; Al Khedr A; Zephir H; Fromont A; Papeix C; Brochet B; Pelletier J; Lebrun C; JAMA Neurol; 2014 Apr; 71(4):436-41. PubMed ID: 24566807 [TBL] [Abstract][Full Text] [Related]
3. Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab. Ziemssen T; Lang M; Tackenberg B; Schmidt S; Albrecht H; Klotz L; Haas J; Lassek C; Cornelissen C; Ettle B; Mult Scler Relat Disord; 2020 Apr; 39():101893. PubMed ID: 31865273 [TBL] [Abstract][Full Text] [Related]
4. Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod. Diem L; Nedeltchev K; Kahles T; Achtnichts L; Findling O Ther Adv Neurol Disord; 2018; 11():1756286418791103. PubMed ID: 30116299 [TBL] [Abstract][Full Text] [Related]
6. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789 [TBL] [Abstract][Full Text] [Related]
7. Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry. Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T; J Neurol; 2019 Nov; 266(11):2672-2677. PubMed ID: 31312958 [TBL] [Abstract][Full Text] [Related]
8. Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients. Leurs CE; van Kempen ZL; Dekker I; Balk LJ; Wattjes MP; Rispens T; Uitdehaag BM; Killestein J Mult Scler; 2018 Oct; 24(11):1453-1460. PubMed ID: 28823223 [TBL] [Abstract][Full Text] [Related]
9. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis. Bergvall N; Lahoz R; Reynolds T; Korn JR Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349 [TBL] [Abstract][Full Text] [Related]
11. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T; CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228 [TBL] [Abstract][Full Text] [Related]
12. Switching from natalizumab to fingolimod: an observational study. Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398 [TBL] [Abstract][Full Text] [Related]
13. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study. Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186 [TBL] [Abstract][Full Text] [Related]
14. Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature. Sriwastava S; Chaudhary D; Srivastava S; Beard K; Bai X; Wen S; Khalid SH; Lisak RP J Neurol; 2022 Mar; 269(3):1678-1687. PubMed ID: 34800168 [TBL] [Abstract][Full Text] [Related]
15. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H; Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031 [TBL] [Abstract][Full Text] [Related]
16. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study. Gajofatto A; Bianchi MR; Deotto L; Benedetti MD Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868 [TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients. Puz P; Lasek-Bal A Med Sci Monit; 2016 Nov; 22():4277-4282. PubMed ID: 27829656 [TBL] [Abstract][Full Text] [Related]
18. Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis. Kim KH; Kim SH; Park NY; Hyun JW; Kim HJ Front Neurol; 2021; 12():714941. PubMed ID: 34305808 [No Abstract] [Full Text] [Related]
19. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Alping P; Frisell T; Novakova L; Islam-Jakobsson P; Salzer J; Björck A; Axelsson M; Malmeström C; Fink K; Lycke J; Svenningsson A; Piehl F Ann Neurol; 2016 Jun; 79(6):950-8. PubMed ID: 27038238 [TBL] [Abstract][Full Text] [Related]
20. Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod. Evangelopoulos ME; Koutoulidis V; Andreadou E; Evangelopoulos DS; Kilidireas C Int J Neurosci; 2016 Dec; 126(12):1097-102. PubMed ID: 26727713 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]